Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): A phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial

The Lancet Infectious Diseases

Volumn 14, Issue 8, 2014, Pages 706-715

  Low, Jenny G ^a   Sung, Cynthia ^a   Wijaya, Limin ^b   Wei, Yuan ^c   Rathore, Abhay P S ^a   Watanabe, Satoru ^a   Tan, Boon Hian ^a   Toh, Liying ^a   Chua, Lian Tee ^a   Hou, Yan'an ^a   Chow, Angelia ^a   Howe, Shiqin ^a   Chan, Wing Ki ^a   Tan, Kah Hin ^a   Chung, Jasmine S ^b   Cherng, Benjamin P ^b   Lye, David C ^d   Tambayah, Paul A ^e   Ng, Lee Ching ^f   Connolly, John ^g   Hibberd, Martin L ^h   Leo, Yee Sin ^d   Cheung, Yin Bun ^a,i   Ooi, Eng Eong ^a   Vasudevan, Subhash G ^a   more..

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f NATIONAL ENVIRONMENT AGENCY   (Singapore)

^g AGENCY FOR SCIENCE   (Singapore)

^h GENOME INSTITUTE OF SINGAPORE   (Singapore)

ⁱ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CASTANOSPERMINE 6 BUTYRATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; FLATULENCE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGAPORE;

ADULT; AGED; ANTIVIRAL AGENTS; DENGUE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FEVER; HUMANS; INDOLIZINES; MALE; MIDDLE AGED; PLACEBOS; SINGAPORE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84904762644     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70730-3     Document Type: Article

References (45)

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
2. Racloz V, Ramsey R, Tong S, Hu W Surveillance of dengue fever virus: a review of epidemiological models and early warning systems. PLoS Negl Trop Dis 2012, 6:e1648.
3. Simmons CP, Farrar JJ, Nguyen van Vinh C, Wills B Dengue. N Engl J Med 2012, 366:1423-1432.
4. Gubler DJ Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 2006, 277:3-16.
5. Halstead SB Antibodies determine virulence in dengue. Ann N Y Acad Sci 2009, 1171(suppl 1):E48-E56.
6. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 2010, 12:157-164.
7. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(suppl 12):S7-16.
8. Suaya JA, Shepard DS, Siqueira JB, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009, 80:846-855.
9. Keller TH, Chen YL, Knox JE, et al. Finding new medicines for flaviviral targets. Novartis Found Symp 2006, 277:102-114.
10. Noble CG, Chen YL, Dong H, et al. Strategies for development of dengue virus inhibitors. Antiviral Res 2010, 85:450-462.
11. Botting C, Kuhn RJ Novel approaches to flavivirus drug discovery. Expert Opin Drug Discov 2011, 7:417-428.
12. Lescar J, Luo D, Xu T, et al. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from dengue virus as a target. Antiviral Res 2008, 80:94-101.
13. Sampath A, Padmanabhan R Molecular targets for flavivirus drug discovery. Antiviral Res 2009, 81:6-15.
14. Sessions OM, Barrows NJ, Souza-Neto JA, et al. Discovery of insect and human dengue virus host factors. Nature 2009, 458:1047-1050.
15. Fink J, Gu F, Ling L, et al. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis 2007, 1:e86.
16. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010, 4:e785.
17. Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013, 207:1442-1450.
18. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
19. Halstead SB Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013, 31:4501-4507.
20. Durantel D Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs 2009, 10:860-870.
21. Mehta A, Zitzmann N, Rudd PM, Block TM, Dwek RA Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett 1998, 430:17-22.
22. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol 2000, 74:564-572.
23. Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 2011, 92:453-460.
24. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007, 195:665-674.
25. Watanabe S, Rathore AP, Sung C, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res 2012, 96:32-35.
26. Kaita K, Yoshida E, Kunimoto D, et al. Phase II proof of concept study of celgosivir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis c genotype-1 non responder patients May 19-24, 2007, 442. Digestive Diseases Week, Washington, DC, USA.
27. Dengue: guidelines for diagnosis, treatment, prevention and control 2009, WHO, World Health Organization, Geneva.
28. Lai YL, Chung YK, Tan HC, et al. Cost-effective real-time reverse transcriptase PCR (RT-PCR) to screen for dengue virus followed by rapid single-tube multiplex RT-PCR for serotyping of the virus. J Clin Microbiol 2007, 45:935-941.
29. Sorbera LA, Castaner J, Garcia-Capdevila L Celgosivir. Drugs Future 2005, 30:545-552.
30. Wang WK, Sung TL, Tsai YC, Kao CL, Chang SM, King CC Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J Clin Microbiol 2002, 40:4472-4478.
31. Johnson BW, Russell BJ, Lanciotti RS Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 2005, 43:4977-4983.
32. Rivetz B, Siman-Tov D, Ambal E, et al. New dengue antibody assay with unique differential detection of IgG and IgM antibodies. Clin Biochem 2009, 42:180-184.
33. Rozen-Gagnon K, Moreland NJ, Ruedl C, Vasudevan SG Expression and immunoaffinity purification of recombinant dengue virus 2 NS1 protein as a cleavable SUMOstar fusion. Protein Expr Purif 2012, 82:20-25.
34. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 2002, 40:376-381.
35. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002, 186:1165-1168.
36. Low JG, Ooi EE, Tolfvenstam T, et al. Early dengue infection and outcome study (EDEN)-study design and preliminary findings. Ann Acad Med Singapore 2006, 35:783-789.
37. Low JG, Ong A, Tan LK, et al. The early clinical features of dengue in adults: challenges for early clinical diagnosis. PLoS Negl Trop Dis 2011, 5:e1191.
38. Points to consider on multiplicity issues in clinical trials The European Agency for the Evaluation of Medicinal Products, (accessed April 28, 2014). http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003655.
39. Basford KE, McLachlan GJ Likelihood estimation with normal mixture models. Appl Stat 1985, 34:282-289.
40. Kaiser J, Michael GL A general-purpose method for two-group randomization tests. Stata J 2009, 9:70-85.
41. Tanner L, Schreiber M, Low JG, et al. Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl Trop Dis 2008, 2:e196.
42. Chaterji S, Allen JC, Chow A, Leo YS, Ooi EE Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am J Trop Med Hyg 2011, 84:224-228.
43. Andries AC, Duong V, Ngan C, et al. Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG. PLoS Negl Trop Dis 2012, 6:e1993.
44. Watanabe S, Tan KH, Rathore AP, et al. The magnitude of dengue virus NS1 protein secretion is strain dependent and does not correlate with severe pathologies in the mouse infection model. J Virol 2012, 86:5508-5514.
45. Kliks SC, Nimmanitya S, Nisalak A, Burke DS Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38:411-419.